- Home
- About
- Team
- Today's Market
- Premium
- Research it
- Outlook
- Portfolio
- Mobile
- Trust Equitymaster
- Help
- Free Reports
MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- Indian - mnc pharma
- PFIZER - ORCHID PHARMA LTD
PFIZER vs ORCHID PHARMA LTD - Comparison Results
PFIZER 
Change
Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More
ORCHID PHARMA LTD
Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More
Current Valuations
| PFIZER | ORCHID PHARMA LTD | PFIZER/ ORCHID PHARMA LTD |
|||
|---|---|---|---|---|---|
| P/E (TTM) | x | 31.4 | -0.1 | - | View Chart |
| P/BV | x | 5.0 | 0.1 | 6,923.6% | View Chart |
| Dividend Yield | % | 0.7 | 0.0 | - |
Financials
 PFIZER  ORCHID PHARMA LTD |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| PFIZER Mar-18 |
ORCHID PHARMA LTD Sep-13 |
PFIZER/ ORCHID PHARMA LTD |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 2,365 | 194 | 1,219.1% | |
| Low | Rs | 1,625 | 35 | 4,642.9% | |
| Sales per share (Unadj.) | Rs | 430.3 | 276.5 | 155.6% | |
| Earnings per share (Unadj.) | Rs | 78.7 | -79.2 | -99.4% | |
| Cash flow per share (Unadj.) | Rs | 93.2 | -43.5 | -214.5% | |
| Dividends per share (Unadj.) | Rs | 20.00 | 0 | - | |
| Dividend yield (eoy) | % | 1.0 | 0 | - | |
| Book value per share (Unadj.) | Rs | 586.5 | 53.9 | 1,087.4% | |
| Shares outstanding (eoy) | m | 45.75 | 70.45 | 64.9% | |
| Bonus/Rights/Conversions | - | ESOP | - | ||
| Price / Sales ratio | x | 4.6 | 0.4 | 1,119.5% | |
| Avg P/E ratio | x | 25.3 | -1.4 | -1,753.5% | |
| P/CF ratio (eoy) | x | 21.4 | -2.6 | -812.4% | |
| Price / Book Value ratio | x | 3.4 | 2.1 | 160.2% | |
| Dividend payout | % | 25.4 | 0 | - | |
| Avg Mkt Cap | Rs m | 91,271 | 8,067 | 1,131.5% | |
| No. of employees | `000 | 2.6 | 2.8 | 93.9% | |
| Total wages/salary | Rs m | 3,143 | 2,527 | 124.4% | |
| Avg. sales/employee | Rs Th | 7,484.8 | 6,956.1 | 107.6% | |
| Avg. wages/employee | Rs Th | 1,195.0 | 902.5 | 132.4% | |
| Avg. net profit/employee | Rs Th | 1,369.1 | -1,993.0 | -68.7% | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 19,685 | 19,477 | 101.1% | |
| Other income | Rs m | 1,143 | 407 | 280.7% | |
| Total revenues | Rs m | 20,828 | 19,884 | 104.7% | |
| Gross profit | Rs m | 5,003 | 1,103 | 453.7% | |
| Depreciation | Rs m | 663 | 2,519 | 26.3% | |
| Interest | Rs m | 4 | 5,227 | 0.1% | |
| Profit before tax | Rs m | 5,479 | -6,236 | -87.9% | |
| Minority Interest | Rs m | 0 | 20 | 0.0% | |
| Prior Period Items | Rs m | 0 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | 0 | 511 | 0.0% | |
| Tax | Rs m | 1,878 | -125 | -1,500.3% | |
| Profit after tax | Rs m | 3,601 | -5,580 | -64.5% | |
| Gross profit margin | % | 25.4 | 5.7 | 448.9% | |
| Effective tax rate | % | 34.3 | 2.0 | 1,707.6% | |
| Net profit margin | % | 18.3 | -28.7 | -63.8% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 24,167 | 11,014 | 219.4% | |
| Current liabilities | Rs m | 9,544 | 32,060 | 29.8% | |
| Net working cap to sales | % | 74.3 | -108.1 | -68.7% | |
| Current ratio | x | 2.5 | 0.3 | 737.0% | |
| Inventory Days | Days | 55 | 95 | 58.1% | |
| Debtors Days | Days | 29 | 34 | 85.5% | |
| Net fixed assets | Rs m | 9,514 | 29,440 | 32.3% | |
| Share capital | Rs m | 458 | 705 | 64.9% | |
| "Free" reserves | Rs m | 26,375 | 2,043 | 1,291.2% | |
| Net worth | Rs m | 26,832 | 3,800 | 706.1% | |
| Long term debt | Rs m | 25 | 9,018 | 0.3% | |
| Total assets | Rs m | 36,900 | 46,510 | 79.3% | |
| Interest coverage | x | 1,305.5 | -0.2 | -676,029.0% | |
| Debt to equity ratio | x | 0 | 2.4 | 0.0% | |
| Sales to assets ratio | x | 0.5 | 0.4 | 127.4% | |
| Return on assets | % | 9.8 | -0.8 | -1,285.4% | |
| Return on equity | % | 13.4 | -146.9 | -9.1% | |
| Return on capital | % | 20.4 | -3.7 | -546.7% | |
| Exports to sales | % | 0 | 37.9 | 0.0% | |
| Imports to sales | % | 0 | 22.6 | 0.0% | |
| Exports (fob) | Rs m | NA | 7,378 | 0.0% | |
| Imports (cif) | Rs m | NA | 4,406 | 0.0% | |
| Fx inflow | Rs m | 22 | 7,513 | 0.3% | |
| Fx outflow | Rs m | 1,489 | 5,649 | 26.4% | |
| Net fx | Rs m | -1,466 | 1,865 | -78.6% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 3,318 | 1,682 | 197.3% | |
| From Investments | Rs m | -2,383 | -9,860 | 24.2% | |
| From Financial Activity | Rs m | -1,104 | 6,644 | -16.6% | |
| Net Cashflow | Rs m | -169 | -1,535 | 11.0% | |
Share Holding
| Indian Promoters | % | 0.0 | 32.3 | - | |
| Foreign collaborators | % | 63.9 | 0.0 | - | |
| Indian inst/Mut Fund | % | 7.5 | 4.6 | 163.0% | |
| FIIs | % | 4.9 | 3.3 | 148.5% | |
| ADR/GDR | % | 0.0 | 4.6 | - | |
| Free float | % | 23.7 | 55.3 | 42.9% | |
| Shareholders | 85,207 | 84,811 | 100.5% | ||
| Pledged promoter(s) holding | % | 0.0 | 54.9 | - |
Compare PFIZER With: IPCA LABS NOVARTIS DR. DATSONS LABS MERCK LTD GSK PHARMA
Compare PFIZER With: MYLAN (US) ACTAVIS (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
|
| |
Today's Market
Where Will the Two-Faced Market Go from Here?(Podcast)
The stock markets are very volatile these days. As the Tanushree Bannerjee, the co-head of research here at Equitymaster puts it, stock markets are two-faced.
Related Views on News
ORCHID PHARMA LTD Announces Quarterly Results (2QFY19); Net Profit Up 67.1% (Quarterly Result Update)
Jan 31, 2019 | Updated on Jan 31, 2019For the quarter ended September 2018, ORCHID PHARMA LTD has posted a net profit of Rs 231 m (up 67.1% YoY). Sales on the other hand came in at Rs 1 bn (down 31.9% YoY). Read on for a complete analysis of ORCHID PHARMA LTD's quarterly results.
PFIZER Announces Quarterly Results (3QFY19); Net Profit Up 51.2% (Quarterly Result Update)
Jan 25, 2019 | Updated on Jan 25, 2019For the quarter ended December 2018, PFIZER has posted a net profit of Rs 1 bn (up 51.2% YoY). Sales on the other hand came in at Rs 5 bn (up 12.5% YoY). Read on for a complete analysis of PFIZER's quarterly results.
PFIZER 2017-18 Annual Report Analysis (Annual Result Update)
Jan 1, 2019 | Updated on Jan 1, 2019Here's an analysis of the annual report of PFIZER for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PFIZER. Also includes updates on the valuation of PFIZER.
PFIZER Announces Quarterly Results (2QFY19); Net Profit Down 13.8% (Quarterly Result Update)
Nov 15, 2018 | Updated on Nov 15, 2018For the quarter ended September 2018, PFIZER has posted a net profit of Rs 958 m (down 13.8% YoY). Sales on the other hand came in at Rs 5 bn (down 9.0% YoY). Read on for a complete analysis of PFIZER's quarterly results.
ORCHID PHARMA LTD Announces Quarterly Results (4QFY18); Net Profit Up 50.8% (Quarterly Result Update)
Aug 24, 2018 | Updated on Aug 24, 2018For the quarter ended March 2018, ORCHID PHARMA LTD has posted a net profit of Rs 924 m (up 50.8% YoY). Sales on the other hand came in at Rs 2 bn (down 24.0% YoY). Read on for a complete analysis of ORCHID PHARMA LTD's quarterly results.
More Views on NewsMost Popular
7 Stocks to Profit from Sensex 100,000(The 5 Minute Wrapup)
Feb 4, 2019Tanushree Banerjee explains everything you need to know about the Rebirth of India and Sensex 100,000.
The RCom Bankruptcy: 5 Lessons for Smallcap Investors(Profit Hunter)
Feb 7, 2019Managements of companies can create or ruin their fortunes. Why is management quality such an important factor in valuing businesses? Read on to find out...
Here's What the Biggest 'Rebirth of India' Investors are Doing(The 5 Minute Wrapup)
Feb 5, 2019A roundtable on the 18th of January 2019 had investors with billions of dollars of investment kitty.
The One Real Estate Stock to Buy Now(The 5 Minute Wrapup)
Feb 13, 2019The real estate sector is ready to make a comeback. This is the stock to consider buying.
Do You Have the Stomach to Survive a Small Cap Crash?(Profit Hunter)
Feb 5, 2019While selecting good businesses is relatively easy task in a bearish phase, where most people fail is in having enough patience to hold the quality stocks until recovery.
More|
| |
PFIZER SHARE PRICE
Feb 15, 2019 (Close)
TRACK PFIZER
- Track your investment in PFIZER with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON PFIZER
PFIZER 5-YR ANALYSIS
COMPARE PFIZER WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.